PulseCX’s David Zaritsky’s Named CEO
PulseCX, the Montgomery County, PA-based healthcare communications agency, has a new CEO. Jay Bolling, the former CEO and new Executive Chairman, stated, “I’m very pleased to announce the promotion of David Zaritsky to President & CEO of PulseCX. For the past five years as President, David has been a visionary and an architect of the agency’s evolution, bringing his passion for Experiential Marketing to our brand positioning.”
For Zaritsky the appointment is nothing short of a “dream-come-true.” He credits the trust and leadership that enabled the appointment, and looks forward to tackling assignments with difficult marketing and strategic challenges. He’ll be sure to interact with all level staff members, one of his greatest strengths, fostering his belief that the sum is greater than the individual.
Greg Flynn to Head Ashfield in U.S.
Greg Flynn has been appointed to Ashfield’s Regional President of Commercial and Clinical in the U.S. Most recently Flynn was Regional President in Japan and created the joint venture CMIC Ashfield. In his new role, he will oversee U.S. operations of commercial, clinical, medical information, pharmacovigilance, and market access.
“Through the talent of our people and Ashfield’s commitment to helping improve lives, I have seen the power of what we do in this organization,” Flynn says. The U.S. business has experienced phenomenal growth in the past two years and this new role is an exciting opportunity to carry on the growth. I am excited about the future of Ashfield in the U.S. and being part of the next phase in this company’s journey.”
Adverum Biotechnologies, Inc.
The gene therapy company working toward medical advancement for rare ocular diseases appoints Athena Countouriotis, MD, to Senior Vice President and Chief Medical Officer. Countouriotis’ new position will cover clinical development, medical affairs, biostatistics, pharmacovigilance, and regulatory functions.
Selecta Biosciences, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to eliminating negative immune responses through biologic therapies, elected Patrick J. Zenner to its Board of Directors. Before Selecta, Zenner was President and CEO of Hoffmann-La Roche Inc., North America, the prescription drug unit of Roche, where his career spanned 32 years. He serves as Chairman of the Board of Directors for ArQule, Inc., and West Pharmaceutical Services.
Surface Oncology announced the expansion of their company’s Scientific Advisory Board (SAB) with the addition of David Tuveson, MD, PhD, and Jedd D. Wolchok, MD, PhD, two experts in translational cancer immunology. With their background and experience, they’ll continue to help the SAB bring immunotherapies to those with life-threatening cancers.
Tarveda Therapeutics, Inc.
With more than 20 years of experience in corporate development and biotechnology companies, Michael A. Metzger was recently appointed to Tarveda Therapeutics’ Board of Directors. Currently, Metzger serves as President and COO at Syndax Pharmaceuticals.